KAZANO®

Drug Information Related Patent

Hold Company

TAKEDA PHARMS USA

Learn More

Dosage and Administration

TABLET;ORAL

Specification

EQ 12.5MG BASE 500MG;EQ 12.5MG BASE 1GM

Indication

KAZANO® is used to assist diet and exercise to improve glycemic control in adults with type 2 diabetes.

Use

Instructions for Use

API

ALOGLIPTIN BENZOATE
METFORMIN HYDROCHLORIDE

API Structure

We Supply

ALOGLIPTIN BENZOATE

Note:

In-house Standard
Facility GMP
CDE/DMF/USMF/KOR/ASMF

METFORMIN HYDROCHLORIDE

Note:

CP/BP/EP/JP/USP
Facility GMP
Product GMP
ASMF/USMF/US-FDA/KFDA/WHO/CEP/KDMF

null

Note:

null

Drug Patent

Patent No	Expiration Date
7807689	2028/6/27
8173663	2025/3/15
8288539	2025/6/24
8900638	2029/5/24

API Patent

Patent No	Expiration Date
7807689	2028/6/27
8173663	2025/3/15
8288539	2025/6/24
8900638	2029/5/24

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION